Fulcrum Therapeutics to Participate in Upcoming May Conferences

Rhea-AI Summary

Fulcrum Therapeutics (NASDAQ: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its participation in two upcoming investor conferences in May 2025:

1. The H.C. Wainwright BioConnect Investor Conference at NASDAQ in New York on May 20, 2025

2. The RBC Capital Markets Global Healthcare Conference in New York on May 21, 2025, featuring a fireside chat at 3:35 pm ET

The fireside chat webcast will be available on Fulcrum's investor relations website and will remain accessible for at least 30 days after the presentation.

News Market Reaction

-0.74%

1 alert

-0.74% News Effect

On the day this news was published, FULC declined 0.74%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences:

• H.C. Wainwright BioConnect Investor Conference at NASDAQ
  May 20, 2025
  New York, New York

• RBC Capital Markets Global Healthcare Conference
  May 21, 2025
  Fireside Chat at 3:35 pm ET, Participation link: HERE
  New York, New York

The webcast of the fireside chat will be accessible by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcasts will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentations.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

FAQ

When is Fulcrum Therapeutics (FULC) presenting at the RBC Capital Markets Healthcare Conference in 2025?

Fulcrum Therapeutics will present a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 21, 2025, at 3:35 pm ET in New York.

Which investor conferences is Fulcrum Therapeutics (FULC) attending in May 2025?

Fulcrum Therapeutics is attending two conferences: the H.C. Wainwright BioConnect Investor Conference at NASDAQ on May 20, 2025, and the RBC Capital Markets Global Healthcare Conference on May 21, 2025.

Where can I watch Fulcrum Therapeutics' (FULC) conference presentations?

The conference webcasts can be accessed through the 'Events and Presentations' section of Fulcrum Therapeutics' website at https://ir.fulcrumtx.com/events-and-presentations, with replays available for at least 30 days.

What is Fulcrum Therapeutics' (FULC) main business focus?

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases.